eligibility_summary
Eligible: Adults 18–70 with newly diagnosed DLBCL with follicular lymphoma (stage II–IV), measurable disease (Lugano 2014), ECOG 0–2, LVEF <45%, HBV carriers only if HBV‑DNA negative, adequate organ and marrow function, life expectancy ≥6 months, consent. Exclude: primary/secondary CNS DLBCL, HIV+, active HCV, major cardiovascular disease, severe hypoxemic COPD, uncontrolled infection, or other recent malignancies (except certain cured early cancers).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in newly diagnosed composite DLBCL with FL testing LO-CHOP: lenalidomide (IMiD) + G-CHOP (obinutuzumab + cyclophosphamide, doxorubicin, vincristine, prednisone). Mechanisms/targets: lenalidomide binds cereblon E3 ligase causing IKZF1/3 degradation, boosting T- and NK-cell cytotoxicity and reducing pro-tumor cytokines/angiogenesis, obinutuzumab is a type II anti-CD20 monoclonal antibody depleting CD20+ B cells via ADCC/ADCP and direct cell death, cyclophosphamide (alkylating) DNA crosslinking, doxorubicin (anthracycline) DNA intercalation and topoisomerase II inhibition, vincristine (vinca alkaloid) microtubule inhibition/mitotic arrest, prednisone (glucocorticoid) lymphocyte apoptosis via glucocorticoid receptor. Targets: malignant CD20+ B cells, cereblon/IKZF pathway, DNA integrity, microtubules, and immune effector pathways.